Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins - Summary - MDSpire

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • By

  • Vikrama Raja

  • Carlos Aguiar

  • Nasreen Alsayed

  • Yogeyaa S. Chibber

  • Hussein ElBadawi

  • Michel Farnier

  • Kumari Pushpa

  • Lale Tokgözoglu

  • Alberto Zambon

  • Jean-Pascal Berrou

  • Michel P. Hermans

  • June 4, 2026

  • 0 min

Share

Objective:

To explore the role of remnant cholesterol (RC) in residual cardiovascular risk and the efficacy of fenofibrate-statin combination therapy in managing dyslipidemia.

Key Findings:
  • Remnant cholesterol is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Patients on statin therapy may still experience residual cardiovascular disease risk due to elevated RC.
  • Fenofibrate reduces triglyceride-rich lipoproteins and non-HDL-C when combined with statins.
  • Long-term studies indicate that fenofibrate is safe and well-tolerated as an adjunct therapy.
Interpretation:

Limitations:
  • The article does not provide specific data on the long-term outcomes of fenofibrate-statin therapy in diverse populations.
  • Further research is needed to establish the optimal patient selection for this combination therapy.
Conclusion:

Original Source(s)

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • by Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Michel Farnier, Kumari Pushpa, Lale Tokgözoglu, Alberto Zambon, Jean-Pascal Berrou, Michel P. Hermans

  • June 4, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions